MX2018008464A - Metodos para separar isoformas de anticuerpos monoclonales. - Google Patents

Metodos para separar isoformas de anticuerpos monoclonales.

Info

Publication number
MX2018008464A
MX2018008464A MX2018008464A MX2018008464A MX2018008464A MX 2018008464 A MX2018008464 A MX 2018008464A MX 2018008464 A MX2018008464 A MX 2018008464A MX 2018008464 A MX2018008464 A MX 2018008464A MX 2018008464 A MX2018008464 A MX 2018008464A
Authority
MX
Mexico
Prior art keywords
antibody
charge variants
preparation
methods
monoclonal antibodies
Prior art date
Application number
MX2018008464A
Other languages
English (en)
Inventor
Gangloff Scott
Jang Eun
Pandey Pradeep
Jerajani Kaushal
Original Assignee
Oncobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobiologics Inc filed Critical Oncobiologics Inc
Publication of MX2018008464A publication Critical patent/MX2018008464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Las variantes de carga de una población de anticuerpos expresado de forma recombinante se pueden separar tanto de la molécula del anticuerpo principal como una de la otra. La separación y el aislamiento de las variantes de carga pueden proceder a través de una modulación combinada de concentración de sal y pH durante la elución de la variante de carga a partir de un soporte de intercambio catiónico. Las variantes de carga aisladas pueden ser evaluadas por su contribución a la potencia de la preparación general de anticuerpo. La composición de una preparación de anticuerpos, al menos en términos de la proporción de las variantes de carga y del anticuerpo principal puede así ser controlada, por ejemplo, para una coincidencia biosimilar o para mejorar la potencia de la preparación.
MX2018008464A 2016-01-08 2017-01-06 Metodos para separar isoformas de anticuerpos monoclonales. MX2018008464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662276378P 2016-01-08 2016-01-08
PCT/US2017/012477 WO2017120435A1 (en) 2016-01-08 2017-01-06 Methods for separating isoforms of monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2018008464A true MX2018008464A (es) 2019-05-30

Family

ID=58010365

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008464A MX2018008464A (es) 2016-01-08 2017-01-06 Metodos para separar isoformas de anticuerpos monoclonales.

Country Status (8)

Country Link
US (1) US20190016753A1 (es)
EP (1) EP3400247A1 (es)
JP (1) JP2019504060A (es)
CN (1) CN109641969A (es)
AU (1) AU2017205477A1 (es)
CA (1) CA3010612A1 (es)
MX (1) MX2018008464A (es)
WO (1) WO2017120435A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
AU2008332271C1 (en) * 2007-12-05 2014-04-24 Chugai Seiyaku Kabushiki Kaisha Anti-NR10 antibody and use thereof
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BR112013012422A2 (pt) * 2010-12-21 2016-08-30 Hoffmann La Roche "método para produzir uma preparação de anticorpo e anticorpo anti-her2"

Also Published As

Publication number Publication date
JP2019504060A (ja) 2019-02-14
CN109641969A (zh) 2019-04-16
EP3400247A1 (en) 2018-11-14
CA3010612A1 (en) 2017-07-13
AU2017205477A1 (en) 2018-07-26
WO2017120435A1 (en) 2017-07-13
US20190016753A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
MX2018008464A (es) Metodos para separar isoformas de anticuerpos monoclonales.
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2022011935A (es) Terapeuticos de anticuerpo que se unen a ctla4.
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
BR112018007046A2 (pt) anticorpo isolado ou fragmento de ligação a antígeno, composição farmacêutica, molécula de polinucleotídeo isolado, vetor, célula, e, métodos para inibir o crescimento de um tumor ou de uma célula tumoral e para tratar uma doença ou distúrbio.
BR112017025693A2 (pt) anticorpos anti-cd40 e seus usos
MY187739A (en) Novel anti-pd-1 antibodies
NZ736026A (en) A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
JOP20190283B1 (ar) طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
BR112017020915A2 (pt) ?anticorpo de mamífero isolado ou fragmento de ligação ao antígeno do mesmo, anticorpo caninizado ou fragmento de ligação ao antígeno caninizado do mesmo, anticorpo monoclonal caninizado ou fragmento de ligação ao antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo isolado, proteína de fusão, composição farmacêutica, e, método para diminuir a atividade de uma célula imune?
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
PH12018502451A1 (en) Brain delivery protein
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof
SG10201801219VA (en) Anti-HER2 Antibodies
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
WO2018127791A3 (en) Erbb2 antibodies and uses therefore
BR112017007592A2 (pt) polipeptídeo, composição de polipeptídeos, métodos de produção de polipeptídeo e de detecção de anticorpos, uso de polipeptídeo e kit de reagentes
EA202091973A1 (ru) Конструкции слитых белков, содержащие анти-muc1 антитело и il-15
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения